LINCOLN636.70

Lincoln Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersSIGACHITHEMISMEDBAJAJHCAREAMRUTANJANJAGSNPHARMWANBURYAHCLMcap ₹1,275 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)140.04134.23122.04122.04
Receivable Days (DSO)101.7197.4587.8287.82
Payable Days (DPO)131.46144.93129.29130.60
Cash Conversion Cycle (days)110.2986.7580.5779.26
Working Capital Turnover1.641.581.421.47
Asset Turnover0.830.780.750.75
Cash Conversion (CFO/Net Income)0.681.131.211.21
CFO/EBITDA0.630.921.091.09
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.